Navigation Links
Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results
Date:11/13/2008

SAN FRANCISCO, Nov. 13 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biotechnology company focused on the development of novel drugs for cardiovascular disease, today announced financial results for the three and nine months ended September 30, 2008.

Net operating loss for the three months ended September 30, 2008 was $3.3 million, or $0.14 per share, compared to $5.5 million, or $0.35 per share, for the same period of 2007. Net operating loss for the nine months ended September 30, 2008 totaled $10.2 million, or $0.42 per share, compared to $7.8 million, or $0.54 per share, for the same period of 2007.

Nile reported no revenue for the three and nine months ended September 30, 2008 and 2007, respectively. Research and development expenses were $2.6 million for the three months ended September 30, 2008 compared to $2.2 million for the comparable period of 2007. For the nine months ended September 30, 2008, research and development expenses totaled $7.4 million compared with $3.6 million for the same period of 2007. The quarterly and year-to-date increases were mostly due to increased clinical trial expenses on our lead compound, CD-NP. General and administrative expenses were $0.8 million for the three months ended September 30, 2008 compared to $2.6 million for the comparable period of 2007. For the nine months ended September 30, 2008, general and administrative expenses totaled $3.0 million compared with $3.3 million for the same period of 2007.

At September 30, 2008, Nile had cash and cash equivalents of $7.4 million compared to $10.3 million and $16.2 million on June 30, 2008 and December 31, 2007, respectively. This $8.8 million decrease from December 31, 2007 occurred as cash was used for operations.

"During the quarter we continued to demonstrate the strong potential of our lead compound CD-NP in treating patients with acute heart failure," said Peter Strumph, Chief Executive Officer of Nile. "We are extremely encouraged by our interim Phase 2a clinical trial results to date and look forward to announcing data from the ongoing Phase 1b Maximum Tolerated Dose clinical study of CD-NP in the fourth quarter of 2008. We look forward to continuing to advance the clinical development of CD-NP with the anticipated initiation of our Phase 2b study in early 2009."

Pipeline Development Update

CD-NP

CD-NP is a novel chimeric natriuretic peptide in clinical development for the treatment of ADHF. CD-NP was designed to preserve the favorable effects of current therapies while preventing or attenuating the hypotensive response, and enhancing or preserving renal function. The Company, in conjunction with The Mayo Clinic, currently has three ongoing clinical trials, evaluating the potential clinical utility of CD-NP in patients with acute heart failure.

-- As of the third quarter of 2008, Nile continued enrollment into the

Phase 1b Maximum Tolerated Dose clinical study of CD-NP. The pace of

enrollment is on target with our anticipated announcement of results

from this study by year end. The primary objectives of the study are to

assess the safety and tolerability of intravenous infusions of CD-NP in

patients with heart failure. Key assessments include measurement of

blood pressure, heart rate and kidney function.

-- As of the third quarter of 2008, The Mayo Clinic dosed its first patient

into the National Institutes of Health (NIH) funded Phase 1b Renal

clinical study of CD-NP. The primary objective of this study is to

assess renal, neurohumoral and non-invasive hemodynamic parameters of

intravenous infusions of CD-NP in patients with heart failure. Key

assessments include glomerular filtration rate, tubular function, renal

plasma flow, urine output and mean arterial pressure.

-- As of the third quarter of 2008, Nile announced interim data from its

Phase 2a Hemodynamic clinical study of CD-NP. Enrollment in the study

is ongoing. The primary objective of the study is to assess hemodynamic

effects of intravenous infusions of CD-NP in patients with heart

failure. Key assessments include measurement of pulmonary capillary

wedge pressure (PCWP), blood pressure and kidney function.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure; 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties; and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of our product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section of our Annual Report on Form 10-KSB, which was filed with the Securities and Exchange Commission on March 27, 2008. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

Nile Therapeutics, Inc.

(A Development Stage Company)

Condensed Statements of Operations

(unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

-------------------- --------------------

2008 2007 2008 2007

Grant income $ - $ 101,400 $ - $ 101,400

Operating expenses

Research and

development 2,556,900 2,175,558 7,423,738 3,596,835

General and

adminis-

trative 818,761 2,562,891 2,977,263 3,284,387

Total

operating

expenses 3,375,661 4,738,449 10,401,001 6,881,222

Loss from

operations (3,375,661) (4,637,049) (10,401,001) (6,779,822)

Other income (expense)

Interest income 58,451 58,975 290,734 82,937

Interest

expense - (970,330) (137) (1,089,344)

Other expense (3,679) - (46,523) -

Total other

Income

(expense) 54,772 (911,355) 244,074 (1,006,407)

Net loss $(3,320,889) $(5,548,404) $(10,156,927) $(7,786,229)

Basic and

diluted loss

per share $ (0.14) $ (0.35) $ (0.42) $ (0.54)

Weighted-average

common shares

outstanding 24,149,405 15,977,936 24,118,645 14,532,772

Summary Balance Sheet Data

September December

30, 2008 31, 2007

(unaudited)

Cash & cash

Equivalents $ 7,363,926 $16,233,464

Total assets $ 8,408,902 $17,089,328

Total

stockholder

equity $ 7,490,754 $15,199,932


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
2. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
3. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
4. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes
5. Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit
6. Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc.
7. Zevalin Revenues Lead Cell Therapeutics, Inc.s First Quarter 2008 Financial Results
8. Juvaris BioTherapeutics, Inc. Announces the Appointment of Grant E. Pickering as Chief Executive Officer
9. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results
10. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
11. Cell Therapeutics, Inc. Announces Issuance of $51.7 Million of New 2012 Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Bay St. Louis, MS (PRWEB) , ... December 08, 2016 , ... ... with offices that serve commercial and residential clients in and around the Hancock County ... community support for the Hancock County Food Pantry. , The Hancock County Food Pantry ...
(Date:12/8/2016)... ... 2016 , ... Bill Mull Agencies, a Wichita-based firm offering ... central Kansas, is joining the Youth Horizons organization for a charity event that ... Wichita, Youth Horizons works to empower area children from unstable, troubled, or single-parent ...
(Date:12/7/2016)... ... 2016 , ... Students attending Envision’s summer 2017 National ... hands-on experience in an emergency medical simulation, When Care is Hours Away. This ... medical skills that are critical success in a future career and beyond. , ...
(Date:12/7/2016)... ... , ... Kenall Manufacturing, a leader in sealed healthcare lighting for more than ... multi-function, sealed, LED luminaire that meets the needs of everyone in the patient room ... , A 2’ x 4’ model features four modes: reading, ambient, standard and ...
(Date:12/7/2016)... ... 07, 2016 , ... Silhouette Instalift is a simple, minimally ... tightening the skin of the face to create more youthful features. While there ... little downtime, Silhouette Instalift is a novel, minimally invasive facial procedure that lifts ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Texas , Dec. 8, 2016 ... program that brings leading-edge laboratory services and management ... United States , allowing more doctors and ... health care management solutions. Logo - ... Hospital systems, under pressure to contain ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch die CFDA sowie ... – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during the Chinese Congress ... Union Hospital ...
(Date:12/8/2016)... 8, 2016 Dignitana, a world leader in ... Boa® Technology, creator of the award-winning, patented Boa® system, ... with the DigniCap® scalp cooling system. DigniCap® was cleared ... 2015, and is the first medical scalp cooling device ... cooling system features a patented tight-fitting silicone cooling cap ...
Breaking Medicine Technology: